Multiple drug discovery initiatives for tuberculosis are currently ongoing to identify and
develop new potent drugs with novel targets in order to shorten treatment duration. One of the …

Identification of unique leads represents a significant challenge in drug discovery. This hurdle
is magnified in neglected diseases such as tuberculosis. We have leveraged public high-…

Methodologies for preclinical animal model testing of drugs against Mycobacterium tuberculosis
vary from laboratory to laboratory; however, it is unknown if these variations result in …

Background Compounds that can act as agonists for toll-like receptors (TLRs) may be
promising candidates for the development of drugs against infectious diseases and cancer. The …

A series of pyridopyrazine and pyrimidothiazine derivatives have been synthesized and their
activity against FtsZ from Mycobacterium tuberculosis (Mtb) and in vitro antibacterial activity …

New antitubercular agents are needed to combat the spread of multidrug- and extensively
drug-resistant strains of Mycobacterium tuberculosis. The frontline antitubercular drug …

One of the most effective and widely used antituberculosis (anti-TB) drugs is isoniazid (INH),
a prodrug activated via oxidation that forms an adduct with NAD + to inhibit NADH-…

The reductively activated nitroaromatic class of antimicrobials, which include nitroimidazole
and the more metabolically labile nitrofuran antitubercular agents, have demonstrated some …

In preclinical testing of antituberculosis drugs, laboratory-adapted strains of Mycobacterium
tuberculosis are usually used both for in vitro and in vivo studies. However, it is unknown …

Here we describe an experimental murine model that allows for aerosolized antituberculosis
drug efficacy testing. Intrapulmonary aerosol delivery of isoniazid, capreomycin, and …